Physician profile
Leanet Cabrera
NPI 1811455637
$2,062.61
in general payments reported to CMS, 2019-2025
23 companies · $528 in 2025
The $528 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $654 · 2022: $41.30 · 2023: $18.45 · 2024: $822 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $497.05 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $376.14 | 2021-2024 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $234.15 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Revance Therapeutics, INC. | $174.78 | 2024 | Daxxify |
| Astrazeneca Pharmaceuticals Lp | $121.84 | 2025 | Breztri |
| Amarin Pharma, INC. | $108.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.21 | 2024-2025 | Trintellix |
| Abbvie INC. | $79.39 | 2021-2024 | |
| Lilly USA, LLC | $72.35 | 2021 | |
| Esperion Therapeutics, INC. | $47.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.36 | 2021 | |
| Lundbeck LLC | $29.17 | 2024 | Rexulti |
| Urovant Sciences INC | $27.97 | 2022 | |
| Viiv Healthcare Company | $21.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.41 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.15 | 2021 | |
| Kci USA, INC. | $18.45 | 2023 | Activ.A.C. |
| Kowa Pharmaceuticals America, INC. | $16.28 | 2021 | |
| Merck Sharp & Dohme LLC | $14.87 | 2021 | |
| Currax Pharmaceuticals LLC | $14.24 | 2021 | |
| Horizon Therapeutics Plc | $13.59 | 2021 | |
| Radius Health, INC. | $12.84 | 2021 | |
| Glaxosmithkline, LLC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanet Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.